Kidney tumor treatment depends on the nature of the growth, its size and location, whether it has spread, kidney function and overall health. Options may include monitoring, surgery, ablation or medicines. Not every kidney tumour is cancerous, and not every tumour requires immediate surgery.
This guide focuses on adult kidney tumours, particularly renal cell carcinoma. Cancers arising in the kidney’s urine-collecting system and childhood kidney tumours require different treatment pathways.
A kidney tumour is an abnormal growth of cells within the kidney. It may be benign, meaning non-cancerous, or malignant, meaning cancerous.
Examples of benign kidney tumours include oncocytoma and classical angiomyolipoma. Renal cell carcinoma, or RCC, is the most common kidney cancer in adults. A scan finding described as a “renal mass” does not automatically establish its exact diagnosis.
Many kidney cancers cause no obvious symptoms initially and are discovered during imaging performed for another reason.
Possible symptoms include:
These symptoms can have several causes. Their presence does not confirm cancer, but they should be assessed. Painless blood in urine needs prompt medical evaluation.
Assessment combines the clinical history, examination, laboratory investigations and imaging. Additional scans may be needed to establish the extent of a suspected cancer.
| Investigation | What it may help assess |
|---|---|
| Ultrasound | An initial kidney abnormality or mass. |
| CT scan | The tumour’s size, location and extent. |
| MRI | Additional detail when clinically appropriate. |
| Blood and urine tests | Kidney function and other relevant abnormalities. |
| Selected biopsy | Tissue characteristics that may influence management. |
Not every person needs every investigation. The choice depends on the findings and the questions that need answering.
No. Biopsy is particularly useful when the result could change treatment. It may be considered before surveillance and is recommended before ablation or systemic treatment when no previous tissue diagnosis is available.
Some patients proceed to surgery based on imaging and clinical assessment, with the removed tissue examined afterwards.
The treatment discussion should consider:
Ask whether the aim is to remove the tumour, control its growth or relieve symptoms. These goals influence the recommended approach.
Active surveillance involves scheduled imaging and clinical review rather than immediate intervention. Treatment can be reconsidered if the tumour changes or other concerns emerge.
It may be appropriate for selected small renal masses, particularly when other health conditions make treatment more burdensome. Selection also considers tumour features, kidney function and personal preferences.
Surveillance requires a clear follow-up plan. It should include the timing of scans, who reviews the results and what changes would prompt treatment. It is not suitable for every tumour.
Partial nephrectomy removes the tumour while preserving the remaining kidney tissue. It is an important option for suitable localised tumours.
Preserving kidney tissue can help maintain renal function. However, suitability depends on tumour anatomy, surgical complexity and the ability to remove it safely.
Radical nephrectomy removes the affected kidney and surrounding tissue as required. It may be recommended when partial removal is unsuitable.
The decision should account for cancer control and the function expected from the remaining kidney.
Ablation destroys tumour tissue using techniques such as freezing or heat. It may be considered for selected small tumours, including in people who are unsuitable for surgery.
Follow-up imaging remains necessary, and additional treatment may sometimes be required.
Immunotherapy helps the immune system act against cancer. Targeted medicines interfere with pathways involved in cancer growth.
These treatments are important options for advanced or recurrent RCC. Selected patients at higher risk of recurrence may also be offered immunotherapy after surgery. The choice depends on cancer characteristics, previous treatment and health status.
Conventional chemotherapy has a limited role in common RCC, although it may be used for certain other kidney cancer types.
For additional background, read about treatments and technologies used in kidney tumour care.
Radiotherapy can help control symptoms or treat selected cancer sites. Specialised stereotactic radiotherapy may also be considered for selected localised tumours when surgery is unsuitable.
Supportive care can address pain, fatigue, nutrition and emotional concerns alongside cancer treatment.
Potential complications include:
The consent discussion should explain the risks relevant to the planned procedure and the individual patient.
Recovery varies with the operation, general health and any complications. Follow the discharge instructions for wound care, medicines, activity and return to work.
Seek urgent assessment after surgery for fever, increasing pain, concerning wound changes, breathing difficulty or other symptoms identified in the discharge plan. Attend the appointment to discuss the tissue report and any further treatment.
Many people live well with one functioning kidney. Removing a kidney does not automatically mean dialysis will be needed.
However, long-term health depends partly on the remaining kidney’s function. Monitoring may include blood pressure, blood tests for filtration and urine tests for protein. Inform healthcare professionals that you have one kidney when discussing medicines or procedures.
Diet and fluid advice should reflect kidney function and other medical conditions.
Follow-up helps assess kidney function, treatment complications and possible recurrence. The schedule depends on the tumour’s characteristics and the treatment received.
Confirm which scans and blood tests are planned, when they are due and who will review them.
No. Some kidney tumours are benign. Imaging and, when appropriate, tissue examination help establish the diagnosis.
No. Selected small masses may be managed with active surveillance after individual assessment.
Sometimes. Partial nephrectomy preserves kidney tissue when it is a suitable and safe option.
No. Tumour characteristics and overall health influence whether ablation is appropriate.
Not necessarily. Many people manage with one functioning kidney; the remaining kidney’s health is important.
No. Surgery, immunotherapy and targeted medicines have important roles. Chemotherapy is uncommon for typical RCC.
Yes. Follow-up assesses recovery, kidney function and the possibility of recurrence.
Conclusion
Kidney tumor treatment requires an individual assessment of the growth, kidney function and overall health. Options range from surveillance to surgery, ablation and medicines.
Understanding the diagnosis, treatment goals, potential complications and follow-up plan helps patients take part in informed decisions. Blood in urine or persistent unexplained symptoms should receive medical assessment.
Medical disclaimer: This article provides general educational information and does not replace personalised medical advice, diagnosis or treatment. Investigations, treatment and recovery require individual clinical assessment.
Editorial note: The existing webpage could not be retrieved, so this is a fresh replacement draft.